Zur Rose Group AG

Investor Presentation • May 1, 2023

Zur Rose Group Conference call: Focusing on B2C core business

Walter Hess | Marcel Ziwica 3 February 2023

Draft\202206_Project Blossom_Management Session_v38.pptx

• −
• −
• −

ibdroot\projects\IBD-LN\stag2022A\693945_1\06. Materials Received\04. H&F Presentation\20220621 H&F

• −
• −

ibdroot\projects\IBD-LN\stag2022A\693945_1\06. Materials Received\04. H&F Presentation\20220621 H&F

Draft\202206_Project Blossom_Management Session_v38.pptx

• −
• −
• −

−

−

Draft\202206_Project Blossom_Management Session_v38.pptx

ibdroot\projects\IBD-LN\stag2022A\693945_1\06. Materials Received\04. H&F Presentation\20220621 H&F

• −
• −
  • −
  • −
  • −
• −

• −
• −
• −
• −

Transaction details: Securing Zur Rose Group's strategy and strengthening balance sheet significantly

Rationale	- Strategic step to purely focus on B2C core business with priority on eRx Germany — Transaction to finance strategy and to strengthen balance sheet - Maximum development potential for Swiss business with Migros/Medbase
Transaction	– Sale of the entire operating business in Switzerland - Revenue 2022: CHF 687m - Expected EBITDA margin 2022: approx. 3% - Proceeds of approx. CHF 360m, including - CHF 15m sale of IP rights to Zur Rose Suisse AG - CHF 47m earn-out based on 2023 EBITDA target, paid in Q2 2024 - Zur Rose Group pro forma equity ratio of 73% – Zur Rose Group pro forma net debt reduced to CHF 30m from CHF 390m — Sale of Swiss property and land has been initiated
Execution period	- Contracts signed on February 2nd by Zur Rose Group and Migros/Medbase - - Closing subject to regulatory approval, envisaged by Q2 2023

Timeline: Swift execution and closing of transaction expected in the first half of 2023

Zur Rose Group